{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:31:45Z","timestamp":1790962305079,"version":"4.1.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"am","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.semarthrit.2020.01.006","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T15:50:46Z","timestamp":1580226646000},"page":"480-491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand?"],"prefix":"10.1016","volume":"50","author":[{"given":"Muriel","family":"Elhai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Avouac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6149-0002","authenticated-orcid":false,"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2020.01.006_bib0001","doi-asserted-by":"crossref","first-page":"17074","DOI":"10.1038\/nrdp.2017.74","article-title":"Idiopathic pulmonary fibrosis","volume":"3","author":"Martinez","year":"2017","journal-title":"Nat Rev Dis Primer"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0002","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthr Rheum"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0003","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41584-018-0062-0","article-title":"Major lung complications of systemic sclerosis","volume":"14","author":"Denton","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0004","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/sarh.2002.50012","article-title":"Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment","volume":"32","author":"Schnabel","year":"2003","journal-title":"Semin Arthr Rheum"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0005","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.semarthrit.2013.08.004","article-title":"Burden of disease in treated rheumatoid arthritis patients: going beyond the joint","volume":"43","author":"Cutolo","year":"2014","journal-title":"Semin Arthr Rheum"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2019.04.005","article-title":"Impact of the pattern of interstitial lung disease on mortality in rheumatoid arthritis: a systematic literature review and meta-analysis","author":"Singh","year":"2019","journal-title":"Semin Arthr Rheum"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0007","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.semarthrit.2017.03.019","article-title":"Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis","volume":"47","author":"Hax","year":"2017","journal-title":"Semin Arthr Rheum"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0008","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.rdc.2015.04.006","article-title":"Management of systemic-sclerosis-associated interstitial lung disease","volume":"41","author":"Silver","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0009","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ats\/ers\/jrs\/alat clinical practice guideline: treatment of idiopathic pulmonary fibrosis. an update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2015.07.008","article-title":"Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature","author":"Giuggioli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0011","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.autrev.2017.07.018","article-title":"How I treat patients with systemic sclerosis in clinical practice","volume":"16","author":"Rossi","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0012","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0013","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1164\/rccm.201902-0456OC","article-title":"Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis","volume":"200","author":"Dempsey","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0014","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0015","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0016","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0017","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0018","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0019","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.resinv.2018.06.001","article-title":"Significance of molecular biomarkers in idiopathic pulmonary fibrosis: a mini review","volume":"56","author":"Chiba","year":"2018","journal-title":"Respir Investig"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0020","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1136\/thx.36.11.801","article-title":"Alveolar response to injury","volume":"36","author":"Bowden","year":"1981","journal-title":"Thorax"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0021","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1164\/ajrccm\/148.3.637","article-title":"KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease","volume":"148","author":"Kohno","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0022","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.bbrc.2005.10.144","article-title":"KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts","volume":"338","author":"Ohshimo","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0023","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1164\/ajrccm.165.3.2107134","article-title":"Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases","volume":"165","author":"Ohnishi","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0024","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4759040","article-title":"Comparative study of circulating MMP-7, CCL18, KL-6, SP-A, and sp-d as disease markers of idiopathic pulmonary fibrosis","volume":"2016","author":"Hamai","year":"2016","journal-title":"Dis Markers"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0025","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2796.2006.01704.x","article-title":"Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases","volume":"260","author":"Satoh","year":"2006","journal-title":"J Intern Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0026","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1378\/chest.108.2.311","article-title":"KL-6: a serum marker for interstitial pneumonia","volume":"108","author":"Kobayashi","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0027","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2466-12-55","article-title":"The elevation of serum napsin a in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D","volume":"12","author":"Samukawa","year":"2012","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0028","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/crj.12341","article-title":"Serum krebs von den lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients","volume":"11","author":"Hu","year":"2017","journal-title":"Clin Respir J"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0029","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.rmed.2014.04.009","article-title":"Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis","volume":"108","author":"Ohshimo","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.resinv.2016.09.003","article-title":"Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis","volume":"55","author":"Wakamatsu","year":"2017","journal-title":"Respir Investig"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0031","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2796.2006.01704.x","article-title":"Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases","volume":"260","author":"Satoh","year":"2006","journal-title":"J Intern Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0032","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1440-1843.2006.00834.x","article-title":"Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis","volume":"11","author":"Yokoyama","year":"2006","journal-title":"Respirol Carlton Vic"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0033","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1111\/crj.12946","article-title":"The serum KL-6 levels in untreated idiopathic pulmonary fibrosis can naturally decline in association with disease progression","volume":"12","author":"Ishii","year":"2018","journal-title":"Clin Respir J"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0034","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.jtcvs.2013.09.050","article-title":"Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer","volume":"147","author":"Sato","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0035","doi-asserted-by":"crossref","first-page":"L3","DOI":"10.1152\/ajplung.90637.2008","article-title":"Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis","volume":"299","author":"Collard","year":"2010","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0036","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0037","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00408-013-9530-0","article-title":"Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis","volume":"192","author":"Kishaba","year":"2014","journal-title":"Lung"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0038","first-page":"3","article-title":"Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis","author":"Sokai","year":"2017","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0039","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1164\/ajrccm.158.5.9803115","article-title":"Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis","volume":"158","author":"Yokoyama","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0040","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12890-016-0249-6","article-title":"Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis","volume":"16","author":"Guiot","year":"2016","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0041","doi-asserted-by":"crossref","DOI":"10.1002\/art.40815","article-title":"Performance of candidate serum biomarkers for systemic sclerosis-interstitial lung disease","author":"Elhai","year":"2019","journal-title":"Arthr Rheumatol Hoboken NJ"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0042","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.rmed.2004.04.003","article-title":"Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT","volume":"98","author":"Kinoshita","year":"2004","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0043","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1259\/bjr\/65287605","article-title":"Comparison of pulmonary thin section CT findings and serum KL-6 levels in patients with sarcoidosis","volume":"84","author":"Honda","year":"2011","journal-title":"Br J Radiol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0044","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3899\/jrheum.080633","article-title":"Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma","volume":"36","author":"Hant","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0045","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3899\/jrheum.100591","article-title":"Use of serum clara cell 16-kDa (CC16) levels as a potential indicator of active pulmonary fibrosis in systemic sclerosis","volume":"38","author":"Hasegawa","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0046","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/imj.12754","article-title":"Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study","volume":"45","author":"Chen","year":"2015","journal-title":"Intern Med J"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0047","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/s41598-017-01685-5","article-title":"Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study","volume":"7","author":"Oda","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0048","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10067-015-3167-8","article-title":"Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study","volume":"35","author":"Oguz","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0049","first-page":"1112","article-title":"Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis","volume":"31","author":"Yanaba","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0050","first-page":"414","article-title":"Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato\/polymyositis","volume":"26","author":"Kum\u00e1novics","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0051","first-page":"27","article-title":"Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement","volume":"28","author":"Bonella","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0052","article-title":"Follow-up of serum KL-6 lung fibrosis biomarker levels in 173 patients with systemic sclerosis","volume":"32","author":"Kum\u00e1novics","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0053","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00296-018-3987-3","article-title":"Elevated serum krebs von den lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease","volume":"38","author":"Benyamine","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0054","doi-asserted-by":"crossref","first-page":"e13542","DOI":"10.1097\/MD.0000000000013542","article-title":"Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody: a retrospective cohort study","volume":"97","author":"Yamaguchi","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0055","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1378\/chest.109.5.1276","article-title":"Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis","volume":"109","author":"Kobayashi","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0056","first-page":"1112","article-title":"Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis","volume":"31","author":"Yanaba","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0057","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00296-018-3987-3","article-title":"Elevated serum krebs von den lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease","volume":"38","author":"Benyamine","year":"2018","journal-title":"Rheumatol Int"},{"issue":"6 Suppl 86","key":"10.1016\/j.semarthrit.2020.01.006_bib0058","first-page":"S-138-144","article-title":"Follow-up of serum KL-6 lung fibrosis biomarker levels in 173 patients with systemic sclerosis","volume":"32","author":"Kum\u00e1novics","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0059","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.rmed.2012.09.001","article-title":"Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels","volume":"106","author":"Horimasu","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0060","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1164\/rccm.200906-0953OC","article-title":"Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a Dutch cohort","volume":"182","author":"van Moorsel","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0061","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2350-15-4","article-title":"Differences in serum sp-d levels between German and Japanese subjects are associated with SFTPD gene polymorphisms","volume":"15","author":"Horimasu","year":"2014","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0062","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1164\/rccm.201505-0862OC","article-title":"Plasma surfactant protein-d, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias","volume":"194","author":"White","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0063","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S2213-2600(17)30430-7","article-title":"An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre profile cohort study","volume":"5","author":"Maher","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0064","first-page":"155","article-title":"Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis","volume":"26","author":"Barlo","year":"2009","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0065","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1378\/chest.08-2209","article-title":"Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis","volume":"135","author":"Kinder","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0066","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1183\/09031936.02.00081102","article-title":"Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis","volume":"19","author":"Greene","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0067","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1378\/chest.11-2735","article-title":"Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis","volume":"143","author":"Song","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0068","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1378\/chest.124.6.2119","article-title":"Study of clara cell 16, KL-6, and surfactant protein-D in serum as disease markers in pulmonary sarcoidosis","volume":"124","author":"Janssen","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0069","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1750-1172-8-53","article-title":"Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis","volume":"8","author":"Bonella","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.resinv.2012.02.001","article-title":"Utility of KL-6\/MUC1 in the clinical management of interstitial lung diseases","volume":"50","author":"Ishikawa","year":"2012","journal-title":"Respir Investig"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0071","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ijc.26007","article-title":"Krebs von den lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer","volume":"130","author":"Tanaka","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0072","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.rmed.2017.08.021","article-title":"Serum surfactant protein d predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone","volume":"131","author":"Ikeda","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0073","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168552","article-title":"Increased expression of CC16 in patients with idiopathic pulmonary fibrosis","volume":"11","author":"Buend\u00eda-Rold\u00e1n","year":"2016","journal-title":"PLoS one"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0074","first-page":"587","article-title":"Tumour markers in rheumatoid arthritis-associated interstitial lung disease","volume":"34","author":"Wang","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1165\/rcmb.2005-0239OC","article-title":"The role of CCL12 in the recruitment of fibrocytes and lung fibrosis","volume":"35","author":"Moore","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0076","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.autrev.2011.04.019","article-title":"Angiogenic cytokines and growth factors in systemic sclerosis","volume":"10","author":"Liakouli","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0077","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1034\/j.1399-3003.1999.14b23.x","article-title":"Clinical significance of MCP-1 levels in balf and serum in patients with interstitial lung diseases","volume":"14","author":"Suga","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0078","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3899\/jrheum.120725","article-title":"Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis","volume":"40","author":"De Lauretis","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0079","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1183\/13993003.01558-2014","article-title":"CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0080","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/art.40171","article-title":"CCL2 in the circulation predicts long-term progression of interstitial lung disease in patients with early systemic sclerosis: data from two independent cohorts","volume":"69","author":"Wu","year":"2017","journal-title":"Arthr Rheumatol Hoboken NJ"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0081","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1164\/rccm.200808-1201OC","article-title":"Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis","volume":"179","author":"Prasse","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0082","first-page":"1","article-title":"Pirfenidone exerts a suppressive effect on CCL18 expression in U937-derived macrophages partly by inhibiting STAT6 phosphorylation","author":"Saito","year":"2016","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0083","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.chest.2016.03.004","article-title":"High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression, and reduced survival in systemic sclerosis","volume":"150","author":"Hoffmann-Vold","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0084","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1002\/art.21257","article-title":"Serum pulmonary and activation-regulated chemokine\/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis","volume":"52","author":"Kodera","year":"2005","journal-title":"Arthr Rheum"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0085","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3899\/jrheum.120997","article-title":"Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?","volume":"40","author":"Elhaj","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0086","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1164\/rccm.201309-1592OC","article-title":"C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis","volume":"189","author":"Vuga","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0087","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/thoraxjnl-2013-204596","article-title":"Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis","volume":"70","author":"DePianto","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0088","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/exd.13724","article-title":"CXCL13 produced by macrophages due to fli1 deficiency may contribute to the development of tissue fibrosis, vasculopathy and immune activation in systemic sclerosis","volume":"27","author":"Taniguchi","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0089","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/bjd.17079","article-title":"Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis","volume":"179","author":"Chen","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0090","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1373\/49.9.1510","article-title":"Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis","volume":"49","author":"Rothkrantz-Kos","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0091","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1378\/chest.124.1.186","article-title":"Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation","volume":"124","author":"Grutters","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0092","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1006\/bbrc.2001.5253","article-title":"YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes","volume":"285","author":"De Ceuninck","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0093","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.rmed.2010.09.012","article-title":"Serum and balf YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis","volume":"105","author":"Korthagen","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0094","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00408-014-9647-9","article-title":"Evaluation of circulating YKL-40 levels in idiopathic interstitial pneumonias","volume":"192","author":"Korthagen","year":"2014","journal-title":"Lung"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0095","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.rmed.2004.09.016","article-title":"Increased serum YKL-40 in patients with pulmonary sarcoidosis\u2013a potential marker of disease activity?","volume":"99","author":"Johansen","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0096","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.3899\/jrheum.170373","article-title":"Clinical utility of YKL-40 in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"44","author":"Hozumi","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0097","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2249.1992.tb06877.x","article-title":"Circulating intercellular adhesion molecule-1 (ICAM-1) antigen in sera of patients with idiopathic pulmonary fibrosis","volume":"89","author":"Shijubo","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0098","doi-asserted-by":"crossref","first-page":"e88150","DOI":"10.1371\/journal.pone.0088150","article-title":"Serum adhesion molecule levels as prognostic markers in patients with early systemic sclerosis: a multicentre, prospective, observational study","volume":"9","author":"Hasegawa","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0099","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1371\/journal.pmed.0050093","article-title":"MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis","volume":"5","author":"Rosas","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0100","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.rmed.2015.06.003","article-title":"Serum metalloproteinases 1 and 7 in the diagnosis of idiopathic pulmonary fibrosis and other interstitial pneumonias","volume":"109","author":"Morais","year":"2015","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0101","doi-asserted-by":"crossref","first-page":"24097","DOI":"10.3390\/ijms141224097","article-title":"MMP-7 and fcDNA serum levels in early NSCLC and idiopathic interstitial pneumonia: preliminary study","volume":"14","author":"Ulivi","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0102","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/resp.12920","article-title":"Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis","volume":"22","author":"Tzouvelekis","year":"2017","journal-title":"Respirol Carlton Vic"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0103","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00074-2016","article-title":"MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis","volume":"3","author":"Bauer","year":"2017","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0104","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1073\/pnas.092134099","article-title":"Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans","volume":"99","author":"Zuo","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0105","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1164\/rccm.201411-1950OC","article-title":"Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers","volume":"191","author":"Doyle","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0106","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2172-14-9","article-title":"Serum biomarker analysis of collagen disease patients with acute-onset diffuse interstitial lung disease","volume":"14","author":"Oka","year":"2013","journal-title":"BMC Immunol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0107","doi-asserted-by":"crossref","first-page":"L1046","DOI":"10.1152\/ajplung.00139.2012","article-title":"Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis","volume":"303","author":"Naik","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0108","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.resinv.2014.12.003","article-title":"Serum level of periostin can predict long-term outcome of idiopathic pulmonary fibrosis","volume":"53","author":"Tajiri","year":"2015","journal-title":"Respir Investig"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0109","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bjd.12117","article-title":"Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis","volume":"168","author":"Yamaguchi","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0110","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jdermsci.2018.02.001","article-title":"Pro-fibrotic phenotype of human skin fibroblasts induced by periostin via modulating TGF-\u03b2 signaling","volume":"90","author":"Kanaoka","year":"2018","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0111","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S2213-2600(15)00048-X","article-title":"Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre profile study","volume":"3","author":"Jenkins","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0112","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1440-1843.1996.tb00043.x","article-title":"Clinical evaluation of serum type IV collagen 7S in idiopathic pulmonary fibrosis","volume":"1","author":"Kasuga","year":"1996","journal-title":"Respirol Carlton Vic"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0113","doi-asserted-by":"crossref","first-page":"e6617","DOI":"10.1097\/MD.0000000000006617","article-title":"Association of serum levels of laminin, type IV collagen, procollagen III N-terminal peptide, and hyaluronic acid with the progression of interstitial lung disease","volume":"96","author":"Su","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0114","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1183\/09031936.95.08091559","article-title":"Predictive value of serum III procollagen for diagnosis of pulmonary involvement in patients with scleroderma","volume":"8","author":"Diot","year":"1995","journal-title":"Eur Respir J"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0115","first-page":"68","article-title":"Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis","volume":"30","author":"Allanore","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0116","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/rheumatology\/ker442","article-title":"Increased serum comp predicts mortality in SSc: results from a longitudinal study of interstitial lung disease","volume":"51","author":"Hesselstrand","year":"2012","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0117","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00141013","article-title":"Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression","volume":"43","author":"Chien","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0118","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-2600(16)30421-0","article-title":"Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial","volume":"5","author":"Raghu","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0119","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10067-017-3878-0","article-title":"The serum level and significance of lysyl oxidase-like 2 in patients with rheumatoid arthritis-associated interstitial lung disease","volume":"37","author":"Fu","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0120","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1164\/rccm.201203-0506OC","article-title":"Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses","volume":"187","author":"Kahloon","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0121","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/eji.201141856","article-title":"Chronic smoke exposure induces rheumatoid factor and anti-heat shock protein 70 autoantibodies in susceptible mice and humans with lung disease","volume":"42","author":"Newkirk","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0122","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1164\/rccm.200810-1534OC","article-title":"Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis","volume":"179","author":"Moeller","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0123","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12931-017-0623-9","article-title":"Fibrocyte measurement in peripheral blood correlates with number of cultured mature fibrocytes in vitro and is a potential biomarker for interstitial lung disease in rheumatoid arthritis","volume":"18","author":"Just","year":"2017","journal-title":"Respir Res"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0124","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.gene.2015.02.065","article-title":"Discovery and validation of extracellular\/circulating microRNAs during idiopathic pulmonary fibrosis disease progression","volume":"562","author":"Yang","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0125","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13000-016-0583-2","article-title":"Plasma microRNAs are associated with acute exacerbation in idiopathic pulmonary fibrosis","volume":"11","author":"Min","year":"2016","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0126","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12891-017-1389-4","article-title":"Plasma miRNA expression profiles in rheumatoid arthritis associated interstitial lung disease","volume":"18","author":"Oka","year":"2017","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0127","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-016-1054-6","article-title":"miR-155 in the progression of lung fibrosis in systemic sclerosis","volume":"18","author":"Christmann","year":"2016","journal-title":"Arthr Res Ther"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0128","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1186\/ar3486","article-title":"Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease","volume":"13","author":"Truchetet","year":"2011","journal-title":"Arthr Res Ther"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0129","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3324\/haematol.12526","article-title":"CXCR4 pos circulating progenitor cells coexpressing monocytic and endothelial markers correlating with fibrotic clinical features are present in the peripheral blood of patients affected by systemic sclerosis","volume":"93","author":"Campioni","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0130","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0131","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6940480","article-title":"Plasma leptin is elevated in acute exacerbation of idiopathic pulmonary fibrosis","volume":"2016","author":"Cao","year":"2016","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0132","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.201206-1109OC","article-title":"Semaphorin 7a+ regulatory t cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-\u03b21-induced pulmonary fibrosis","volume":"187","author":"Reilkoff","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0133","doi-asserted-by":"crossref","DOI":"10.1080\/17476348.2016.1249854","article-title":"Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis","author":"Fukihara","year":"2016","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0134","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.resinv.2016.09.003","article-title":"Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis","volume":"55","author":"Wakamatsu","year":"2017","journal-title":"Respir Investig"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2015.03.005","article-title":"Change in serum marker of oxidative stress in the progression of idiopathic pulmonary fibrosis","volume":"32","author":"Matsuzawa","year":"2015","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0136","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3899\/jrheum.080633","article-title":"Surfactant protein d and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma","volume":"36","author":"Hant","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.01.006_bib0137","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.rmed.2004.04.003","article-title":"Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT","volume":"98","author":"Kinoshita","year":"2004","journal-title":"Respir Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220300068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220300068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:01:49Z","timestamp":1758733309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220300068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":137,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0049017220300068"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.01.006","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}